Opentrons is a private company, founded in 2015. Investors last valued the company at $1B. No public ticker exists for the company.
1 valuation. The latest, $1.8B post-money, was set by the Series C in Sep 2021.
Khosla VenturesLEADSSoftBank Vision Fund 2LEADHHAXLR8R
Y CombinatorKhosla VenturesSoftBank Vision Fund 2Opentrons manufactures liquid-handling lab robots, including the OT-2 and Flex platforms, that automate pipetting for tasks such as NGS library preparation, nucleic acid extraction and PCR. Founded in 2014 in Long Island City, New York, the company also sells OpentronsAI, a tool that lets scientists design and verify protocols using natural language.
The OT-2 became a widely used tool during the fight against COVID-19, and its successor, the Flex robot released in 2023, measures about two feet on each side and is sold as a one-time purchase instead of a robot-as-a-service subscription.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Opentrons.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Opentrons availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Opentrons included.
Lead investors for each round are in the funding timeline.
The routes section explains what is realistically available for a company at this stage.
No. Opentrons is a private company; its shares do not trade on a public exchange.
The last valuation is $1B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
